IL1B and type 2 diabetes mellitus: In a clinical trial of 24 patients with T2DM and obesity injected with exenatide 10 μg twice daily, exenatide was found to reduce TNF‐α, TLR‐2, TLR‐4, IL‐1β, monocyte chemoattractant protein‐1 (MCP‐1) and IL‐6 [103, 104].